Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study (NCT04175431)

🧪 Interventions in This Study

• Abiraterone Acetate (DRUG)
• Prednisone (DRUG)
• Abiraterone (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Patient must have histologically or cytologically documented evidence of prostate adenocarcinoma
2. Patient must previously have undergone radical prostatectomy
3. Patient must previously have undergone either adjuvant or salvage radiation therapy to the prostatic fossa +/- whole pelvis
4. Patient must have a prostate specific antigen (PSA) \>= 0.2 and \< 10 ng/mL. If there is only one PSA value that has risen to \>= 0.2 with this biochemical recurrence, a second PSA value must be confirmed to be within \>= 0.2 and \< 10 ng/mL at least 2 weeks from the first value and within 28 days of enrollment
5. PSA doubling time must be calculated utilizing either all PSA measurements \> 0.1 ng/mL from most recent biochemically-recurred (BCR) or the most recent 3 PSA measurements \> 0.1 ng/mL (if the latter, all 3 PSA measurements must be \> 2 weeks apart to be used in the calculation). PSA doubling time must be \> 3 months and \< 18 months. The Memorial Sloan Kettering PSA doubling time calculator should be used
6. Patient must have no previous evidence of radiographically detectable metastatic prostate cancer by conventional CT and bone scan imaging
7. Patient must have total testosterone level \> 120 ng/dL demonstrated within 42 days of enrollment
8. Patient must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
9. Absolute neutrophil count (ANC) \>= 1.0 X 10\^9/L
10. Platelet count \>= 100 X 10\^9/L
11. Hemoglobin \>= 9 g/dL
12. Potassium \>= 3.5

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (2 Sites)

• University of Pittsburgh Cancer Institute (UPCI) — Pittsburgh, Pennsylvania
• Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington

📞 Contact the Study Coordinator

Phone: (206) 606-1909

Email: jromani@fredhutch.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Prostate Adenocarcinoma

• Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial — Phoenix, Arizona
• Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer — Birmingham, Alabama
• Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer — La Jolla, California
• Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer — Houston, Texas
• Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer — Houston, Texas

Explore by condition: All Prostate Adenocarcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.